ArticleDiabetologia2026

GLP1-E2 therapy delays autoimmune diabetes in late-stage prediabetic NOD mice and potentiates low-dose anti-CD3 therapy for enhanced disease protection.

Laure Degroote et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.